5439042026-10-155439042026-10-152026-10-155439042026-10-15in-capmkt:FinancialYear1Member5439042026-10-15in-capmkt:FinancialYear2Member5439042026-10-15in-capmkt:FinancialYear3Member5439042026-10-152026-10-15in-capmkt:FinancialYear1Member5439042026-10-152026-10-15in-capmkt:FinancialYear2Member5439042026-10-152026-10-15in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure543904Mankind Pharma LimitedMANKINDNOTLISTEDINE634S01028NewAcquisition (including agreement to acquire)true2026-10-1519:00:002026-10-15Mankind Pharma LimitedListed Entity (self)Mankind Pharma (Netherlands) B.V.000true2026-10-152026-10-15falsefalsetruePharmaceutical Industry The funds will be utilized by Mankind Netherlands to acquire a majority stake (i.e., 70%) in ACTx through an investment of EUR 48Mn, to be made in instalments. Said investment is part of the Company’s long term strategy to build a global innovation-led pharmaceutical business. YesAs may be required in compliance with laws of the host countrytrueAs per definitive agreementCash4796000000The Company will make an additional investment of up to EUR 45Mn, in one or more tranches in Mankind Netherlands, aggregating to EUR 50Mn, inclusive of the previously approved investment limit of EUR 5Mn, which will be utilized to invest EUR 48Mn in installments in ACTx for acquiring 70% stake. 4796000000111The Mankind Netherlands is an existing wholly owned subsidiary of the Company, incorporated in Netherlands on August 13, 2026, with the business objective of holding investments in R&D assets and undertaking business development activities focused on the treatment of niche therapies, either through joint ventures or by acquiring strategic interests as opportunities arise. The Mankind Netherlands was incorporated recently, hence turnover is Nil. ACTx, a Belgium-incorporated biotechnology company developing next-generation armed CAR-T (chimeric antigen receptor T cell) therapies for cancer and has a pipeline of next-generation CAR-T assets, with lead programs in non-Hodgkin lymphoma and small cell lung cancer. ACTx R&D activities are led by highly experienced teams located in US and EU. 2026-08-132025-202602024-202502023-20240Netherlands